



Acquisition of *bla*_{IMP-13} on a novel *IncP-7* plasmid in XDR VIM-2-positive *Pseudomonas aeruginosa* belonging to the global high-risk clone ST235 in an agricultural ecosystem

Edited by Stefania Stefa

Sir,

Carbapenem-resistant *Pseudomonas aeruginosa* strains are designated by the World Health Organization (WHO) as critical priority pathogens, which seriously limit the current treatment options. Sequence type (ST) 235 is the most prevalent and widespread clone associated with therapeutic failure [1]. In this regard, a number of genes encoding metallo- β -lactamases (MBLs) have become associated with ST235, which has promoted their dissemination [1,2]. VIM-2 and IMP-13 MBLs exhibit a broad-spectrum activity and their intercontinental spread has been reported in hospital outbreaks [2,3]. Nevertheless, neither co-production of VIM-2 and IMP-13 in a single bacteria species nor fully sequenced plasmids carrying *bla*_{IMP-13} have been described so far.

During a surveillance study conducted to monitor the occurrence of priority pathogens in crops, one carbapenem-resistant *P. aeruginosa* strain, named S810, was isolated from an agricultural soil sample with a history of cattle manure use. Antimicrobial susceptibility testing was performed by disk diffusion, broth microdilution, and/or agar dilution methods according to Clinical and Laboratory Standards Institute (CLSI) guidelines (M100, 31st ed.). Strain S810 was classified as extensively drug-resistant (XDR) because it presented resistance to piperacillin-tazobactam (128/4 mg/L), ceftazidime (64 mg/L), cefepime (64 mg/L), aztreonam (32 mg/L), imipenem (128 mg/L), meropenem (128 mg/L), gentamicin (256 mg/L), tobramycin, amikacin, ciprofloxacin (128 mg/L), norfloxacin, lomefloxacin, ofloxacin, and levofloxacin, but it was susceptible to colistin (0.5 mg/L). Polymerase chain reaction (PCR) screening and Sanger sequencing revealed that the strain was positive for *bla*_{VIM} and *bla*_{IMP} genes.

Whole-genome sequencing of *P. aeruginosa* S810 was performed using an Illumina HiSeq platform (Illumina, San Diego, CA) and *de novo* assembly was conducted using SPAdes v. 3.15.2 and refined with Geneious v. 11.1.5. Bioinformatics tools available from the Center for Genomic Epidemiology (www.cge.dtu.dk) and the Virulence Factor Database (VFDB) database (<http://www.mgc.ac.cn/VFs/>) were used to analyse the data.

The S810 strain belonged to serotype O11 and ST235/CC235, a globally disseminated high-risk clone associated with high virulence and multiple resistance determinants [1,4]. In this regard, virulome analysis of S810 revealed the presence of *aprA* (alkaline protease), *exoU* (cytotoxin), *lasB* (elastase), *plcH* (hemolytic phospholipase C), *plcN* (non-hemolytic phospholipase C), and *toxA* (exotoxin A) genes. Antimicrobial resistance genes to β -lactams (*bla*_{VIM-2}, *bla*_{IMP-13}, *bla*_{OXA-50}, and *bla*_{PAO}), aminoglycosides [*aac*(6')-29b, *aac*(6')-Ib3, *aadA1*, *aph*(3'')-Ib, *aph*(3')-Ib, and *aph*(6)-Id], flu-

oroquinolones (*crpP*), fosfomycin (*fosA*), tetracyclines (*tetC*), phenicols (*catB7* and *cmlA1*), trimethoprim (*dfrA15*), and sulphonamides (*sul1*) were also identified. Additionally, mutations in the quinolone resistance-determining regions of *gyrA* (T83I), *gyrB* (S466F), and *parC* (S87L), in the outer membrane porin *oprD* gene (Δ 588-603), and in efflux pumps expression regulators [*mexR* (V126E, Δ 265-343), *mexZ* (C59W, A159G), *nalC* (F55L), and *armZ* (F61Y, G72A, Q176H, V243A, A262S)] were detected.

Pseudomonas aeruginosa S810 harbored two plasmids, ~140 kb (named pS810a) and ~240 kb (named pS810b), bearing *bla*_{VIM-2} and *bla*_{IMP-13}, respectively, which were transferred separately by conjugation using a rifampicin-resistant mutant of *P. aeruginosa* PAO1 as recipient strain. The complete sequence of the plasmids was obtained from *de novo* assembly followed by gap closure.

The pS810a plasmid was 139,453 bp in length, containing 58.6% GC content and 159 coding regions (CDSs), and could not be assigned to any known incompatibility group. Besides *bla*_{VIM-2}, the plasmid co-harbored *aac*(6')-29b, *aph*(3'')-Ib, *aph*(6)-Id, *cmlA1*, *dfrA15*, and *sul1* genes, and showed a high similarity (71–76% query coverage and 98–99.9% nucleotide identity) to other unknown *Inc* group plasmids from clinical and environmental *P. aeruginosa* and *Pseudomonas putida*, respectively (GenBank accession numbers CP011370.1 and CP003589.1).

In contrast, pS810b was a novel 240,265 bp *IncP-7* plasmid, containing 54.3% GC and 282 CDSs, and was most related to p1160-VIM (32% query coverage and 96.1% nucleotide identity), an ~205.4 kb plasmid harboring *bla*_{VIM-24} of a carbapenem-resistant *P. aeruginosa* strain isolated from a human patient in China [5]. In addition to *bla*_{IMP-13}, pS810b co-harbored *aac*(6')-Ib3, *aadA1*, *sul1*, and *tetC*, and genes encoding resistance to tellurite (*terY3Y2XY1W* and *terZABCDE*), silver (*silESRCBAP*), and mercury (*merRTPCADE*). Variable regions of this plasmid were mostly composed of resistance genes, transposable elements, and genes encoding hypothetical proteins (Fig. 1A).

Analysis of the genetic context of the MBL genes revealed that *bla*_{VIM-2} was associated with the *Inc1025* integron, carrying the *aac*(6')-29b-*bla*_{VIM-2}-*aac*(6')-29b gene cassette array. On the other hand, a novel *Tn402*-like class 1 integron, *Inc2113*, carrying the *bla*_{IMP-13}-*qacG2*-*aac*(6')-Ib3-*aadA1* cassette array, was identified using INTEGRALL (<http://integrall.bio.ua.pt/>). *Inc2113* was also harbored by a novel *Tn21*-derivative transposon, *Tn7362* (18,431 bp), identified using the Transposon Registry (<https://transposon.lstmed.ac.uk/>). In addition to *Inc2113*, *Tn7362* carried genes related to transposition (*tnp*), EAL domain-containing protein (*urf2*), and mercury resistance (*merRTPCADE*) (Fig. 1B).

In conclusion, to the best of our knowledge, this is the first report of the *bla*_{IMP-13} gene in Brazil, co-production of VIM-2 and IMP-13 in a single bacteria species, and a fully sequenced *bla*_{IMP-13}-carrying plasmid. Although the origin of *bla*_{VIM-2} and *bla*_{IMP-13} in agricultural soil was unclear, cattle manure and irrigation water might be sources. The detection of *bla*_{IMP-13} and *bla*_{VIM-2} in an XDR




Fig. 1. Novel IncP-7 plasmid, pS810b, harboring *bla*_{IMP-13} on a novel Tn21-derivative transposon, Tn7362, in extensively drug-resistant *Pseudomonas aeruginosa* ST235 identified in Brazil. A) Comparison between IncP-7 plasmids from *P. aeruginosa* S810 (pS810b, GenBank accession number OL468818.1) isolated from agricultural soil in Brazil and *P. aeruginosa* 1160 (p1160-VIM, GenBank accession number MF144194.2) isolated from a human patient in China. Genes related to antimicrobial resistance, metal resistance, and conjugal transfer are indicated in red, blue, and orange, respectively; hp represents genes encoding hypothetical proteins. The gray arc indicates Tn7362 harboring a novel *bla*_{IMP-13}-containing Tn402-like class 1 integron, In2113. Matches with less than 50% identity and no matches appear as blank spaces. B) Schematic representation of Tn7362 and Tn21. The In2113 integron, carrying the *bla*_{IMP-13}-*qacG2*-*aac*(6')-Ib3-*aadA1* gene cassette array, is shown. Black filled arrows indicate flanking inverted repeats (IR) of transposons and integrons. The vertical bar, diamond, and ellipses represent resolution (*res*), *attI1*, and *attC* sites, respectively. The gray shading denotes shared regions of homology.

P. aeruginosa strain of the ST235 epidemic lineage in agricultural soil represents a threat to food and environmental safety. Therefore, continued monitoring of critical priority bacteria in crops remains necessary to effectively limit the spread of high-risk clones.

Nucleotide sequence accession numbers

Nucleotide sequences of *P. aeruginosa* S810 have been deposited at GenBank under accession numbers: JAJJQH000000000.1 (whole-genome shotgun project), MZ816709.1 (transposon Tn7362), OL468818.1 (plasmid pS810b), and OL468819.1 (plasmid pS810a).

Ethical approval

Not required

Competing interests

None declared

Acknowledgements

The authors thank John Carpenter for the English text review.

Funding

This study was supported by the Fundação de Amparo à Pesquisa do Estado de São Paulo [grant numbers [2018/01890-3](#) and [2021/01655-7](#)], the Coordenação de Aperfeiçoamento de Pessoal de Nível Superior [grant numbers [88887.464733/2019-00](#), [88882.180855/2018-01](#), and Finance code 001], and the Conselho Nacional de Desenvolvimento Científico e Tecnológico [grant number [308914/2019-8](#)].

References

- [1] Treepong P, Kos VN, Guyeux C, Blanc DS, Bertrand X, Valot B, et al. Global emergence of the widespread *Pseudomonas aeruginosa* ST235 clone. Clin Microbiol Infect 2018;24:258–66. doi:[10.1016/j.cmi.2017.06.018](#).
- [2] Del Barrio-Tofiño E, Lopez-Causape C, Oliver A. *Pseudomonas aeruginosa* epidemic high-risk clones and their association with horizontally-acquired β -lactamases: 2020 update. Int J Antimicrob Agents 2020;56:106196. doi:[10.1016/j.ijantimicag.2020.106196](#).
- [3] Santella G, Pollini S, Docquier JD, Mereuta AI, Gutkind G, Rossolini GM, et al. Intercontinental dissemination of IMP-13-producing *Pseudomonas aeruginosa* belonging in sequence type 621. J Clin Microbiol 2010;48:4342–3. doi:[10.1128/JCM.00614-10](#).
- [4] Horcjada JP, Montero M, Oliver A, Sorli L, Luque S, Gomez-Zorrilla S, et al. Epidemiology and treatment of multidrug-resistant and extensively drug-resistant *Pseudomonas aeruginosa* infections. Clin Microbiol Rev 2019;32:e00031–19. doi:[10.1128/CMR.00031-19](#).
- [5] Zeng L, Zhan Z, Hu L, Jiang X, Zhang Y, Feng J, et al. Genetic characterization of a *bla*_{VIM-24}-carrying IncP-7 β plasmid p1160-VIM and a *bla*_{VIM-4}-harboring integrative and conjugative element Tn6413 from clinical *Pseudomonas aeruginosa*. Front Microbiol 2019;10:213. doi:[10.3389/fmicb.2019.00213](#).

Ralf Lopes

João Pedro Rueda Furlan

Eliana Guedes Stehling*

Department of Clinical Analyses, Toxicology and Food Science, School of Pharmaceutical Sciences of Ribeirão Preto, University of São Paulo, Ribeirão Preto, Brazil

*Corresponding author. Mailing address: Av. do Café, s/n, Monte Alegre, Ribeirão Preto, 14040-903, Brazil.

E-mail address: elianags@usp.br (E.G. Stehling)

Revised 1 July 2022